Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Apr 5;18(1):250.
doi: 10.1186/s12913-018-3060-7.

A cross-sectional study of the availability and pharmacist's knowledge of nano-pharmaceutical drugs in Palestinian hospitals

Mohyeddin Assali  1 , Ali Shakaa  2 , Sabaa Abu-Hejleh  2 , Reham Abu-Omar  2 , Nareman Karajeh  2 , Nawal Ajory  2 , Saed Zyoud  2 , Waleed Sweileh  3
Affiliations
Multicenter Study

A cross-sectional study of the availability and pharmacist's knowledge of nano-pharmaceutical drugs in Palestinian hospitals

Mohyeddin Assali et al. BMC Health Serv Res. .

Abstract

Background: Nanomedicine is the medical application of nanomaterials that may have an infinite size with the range less than 100 nm. This science has provided solutions to many of the current limitations in the diagnosis and treatment of diseases. Therefore, the pharmacist's knowledge and awareness of nano-pharmaceutical drugs will increase their availability in the market, and will improve the patient's compliance to their drug therapy. This study aimed to determine the availability of nano-pharmaceutical drugs in Palestinian hospitals and evaluate the extent of pharmacist's knowledge about them.

Methods: A cross-sectional study design questionnaire was used to determine the availability of nano-pharmaceutical drugs based on the database of the ministry of health in the Palestinian hospitals (governmental, private and non- governmental organizations). Moreover, the knowledge of these nano-pharmaceutical drugs among pharmacists working in Palestinian hospitals was assessed based on developed questionnaire from the literature of the pharmaceutical formulations and nano-formulations. The variables were analyzed using Statistical Package for Social Sciences (SPSS 22).

Result: Fifty six pharmacists from 27 hospitals in the West bank completed the survey. The results regarding the availability of nano-pharmaceutical drugs indicated only eight available in hospitals with a frequency range 0-39.3%. Moreover, pharmacist's knowledge in the pharmaceutical formulations was better than that in nano-formulations.

Conclusions: The availability of nano-pharmaceutical drugs in Palestinian hospitals was not adequate due to the lack of various nano-pharmaceutical drugs. The knowledge among pharmacists regarding nano-pharmaceutical drugs should be improved by providing courses in nanomedicine during the undergraduate pharmacy programs.

Keywords: Availability; Knowledge; Nano-pharmaceutical drugs; Palestinian hospitals; Pharmaceutical nano-formulation; Pharmaceutical nanotechnology.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study protocol and the verbal consent procedure were approved by the Ethics Committee of An-Najah National University. The interview content was described to respondents, and an informed verbal consent was obtained before the start of the interview.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

See all similar articles

Cited by

References

    1. Auffan M, Rose J, Bottero J-Y, Lowry GV, Jolivet J-P, Wiesner MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol. 2009;4(10):634–641. doi: 10.1038/nnano.2009.242. - DOI - PubMed
    1. Karn B, Kuiken T, Otto M. Nanotechnology and in situ remediation: a review of the benefits and potential risks. Environ Health Perspect. 2009;117:1823–1831. doi: 10.1289/ehp.0900793. - DOI - PMC - PubMed
    1. Kagan VE, Bayir H, Shvedova AA. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomedicine. 2005;1(4):313–316. doi: 10.1016/j.nano.2005.10.003. - DOI - PubMed
    1. Ghosh S, Ansar W. Nanoparticles’ promises and risks. Springer. 2015. Multidynamic liposomes in nanomedicine: technology, biology, applications, and disease targeting; pp. 167–210.
    1. Webster TJ. Nanomedicine: What’s in a definition? Int J Nanomedicine. 2006;1(2):115. doi: 10.2147/nano.2006.1.2.115. - DOI - PMC - PubMed

Publication types

Substances